Mazdutide
Also referenced as: IBI362
A dual glucagon and GLP-1 receptor agonist with clinical development and approvals in China.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- Clinical Trials
Approved in China for specified indications, initially chronic weight management in 2025; not FDA-approved in the United States.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A dual glucagon and GLP-1 receptor agonist with clinical development and approvals in China.
Approved in China for specified indications, initially chronic weight management in 2025; not FDA-approved in the United States.
Population-specific weight results are not established cardiovascular outcomes; Chinese regulatory decisions are separate from the FDA.
Why It's Being Studied
- Obesity
- Type 2 diabetes
- Dual receptor agonism
Mechanism of Action
Its receptor activity combines appetite-related GLP-1 signalling with glucagon-pathway effects on metabolism.
Its receptor activity combines appetite-related GLP-1 signalling with glucagon-pathway effects on metabolism. Population-specific weight results are not established cardiovascular outcomes; Chinese regulatory decisions are separate from the FDA.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Obesity
- Type 2 diabetes
- Dual receptor agonism
- Subcutaneous clinical formulation
Evidence Summary
Phase 3 GLORY studies support weight loss in the studied Chinese populations; these findings do not establish US approval.
Higher tiers carry more weight. Filled tiers have evidence for Mazdutide; tap to read it.
- Phase 3 GLORY studies support weight loss in the studied Chinese populations; these findings do not establish US approval.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Phase 3 GLORY studies support weight loss in the studied Chinese populations; these findings do not establish US approval.
Reported Adverse Events in Research
- Gastrointestinal adverse effects, discontinuation and long-term safety require attention.
Limitations of Current Evidence
- Population-specific weight results are not established cardiovascular outcomes; Chinese regulatory decisions are separate from the FDA.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Mazdutide | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | Clinical Trials | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous clinical formulation | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Mazdutide — regulatory document